Doc, let's say that there is a specific cancer that has a cure rate of 75% with the current SOC treatment. Knowing that DCVax-L could improve on this, would they make it part of the SOC, or would they wait for patients to not be getting the benefits before making the vaccine. Certainly, all should have their tumors properly preserved, but that's not expensive.
At a much lower-level years ago, I was being treated for a condition for quite a while and still complaining to my Dr. finally he said, I can put you on a more effective drug which worked far better. Accountants virtually dictated trying the cheaper and less effective medication first. I'm wondering if the same approach would happen here.
Without data it would be impossible to say that if you add the vaccine you raise the cure rate to 85%, but if the vaccine isn't added until it's clear the patient is failing on the SOC so vaccine's added and survival increases to 80. I don't think you can really know what would happen without either a trial, or a great deal of historical data.
Gary
Bullish
Market Data 
Markets 
AI
